Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: Report of 5 cases

Ophthalmology

Volumn 119, Issue 9, 2012, Pages 1798-1802

  Saint Jean, Alejandro ^a   Sainz De La Maza, Maite ^a   Morral, Merce ^a   Torras, Josep ^a   Quintana, Ramon ^a   Molina, Juan Jose ^a   Molina Prat, Nicolas ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b CMD Ocular   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; CYANOACRYLATE; ERLOTINIB; PANITUMUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA MELTING; CORNEA PERFORATION; CORNEA ULCER; DRUG WITHDRAWAL; DRY EYE; ECTROPION; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; PENETRATING KERATOPLASTY; PHACOEMULSIFICATION; PRIORITY JOURNAL; PUNCTATE KERATITIS; RETROSPECTIVE STUDY; SLIT LAMP;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CORNEAL PERFORATION; ECTROPION; FEMALE; HUMANS; KERATOPLASTY, PENETRATING; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 84865698364     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.03.002     Document Type: Article

References (43)

1. G. Carpenter, S. Cohen Epidermal growth factor J Biol Chem 265 1990 7709 7712
2. M.R. Schneider, E. Wolf The epidermal growth factor receptor ligands at a glance J Cell Physiol 218 2009 460 466
3. M.W. Saif Colorectal cancer in review: the role of the EGFR pathway Expert Opin Investig Drugs 19 2010 357 369
4. E.K. Rowinsky The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors Annu Rev Med 55 2004 433 457
5. E.R. Brown, F.A. Shepherd Erlotinib in the treatment of non-small cell lung cancer Expert Rev Anticancer Ther 5 2005 767 775
6. C.R. Leemans, B.J. Braakhuis, R.H. Brakenhoff The molecular biology of head and neck cancer Nat Rev Cancer 11 2011 9 22
7. S. Raza, N. Kornblum, V.P. Kancharla Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck Recent Pat Anticancer Drug Discov 6 2011 246 257
8. O.M. Cojocariu, F. Huguet, M. Lefevre, S. Périé Prognosis and predictive factors in head-and-neck cancers [in French] Bull Cancer 96 2009 369 378
9. F.R. Hirsch, M. Varella-Garcia, F. Cappuzzo Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Oncogene 28 Suppl 2009 S32 S37
10. L. Castillo, M.C. Etienne-Grimaldi, J.L. Fischel Pharmacological background of EGFR targeting Ann Oncol 15 2004 1007 1012
11. V. Grunwald, M. Hidalgo The epidermal growth factor receptor: a new target for anticancer therapy Curr Probl Cancer 26 2002 109 164
12. G. Mountzios, K.N. Syrigos A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer Drug Saf 34 2011 175 186
13. V.D. Cataldo, D.L. Gibbons, R. Pérez-Soler, A. Quintás-Cardama Treatment of non-small-cell lung cancer with erlotinib or gefitinib N Engl J Med 364 2011 947 955
14. M. El Zouhairi, A. Charabaty, M.J. Pishvaian Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents Gastrointest Cancer Res 4 2011 15 21
15. Y. Nakamura, C. Sotozono, S. Kinoshita The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis Exp Eye Res 72 2001 511 517
16. H. Watanabe, Y. Ohashi, S. Kinoshita Distribution of epidermal growth factor in rat ocular and periocular tissues Graefes Arch Clin Exp Ophthalmol 231 1993 228 232
17. C.G. Foerster, C. Cursiefen, F.E. Kruse Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody) Cornea 27 2008 612 614
18. K.S. Johnson, F. Levin, D.S. Chu Persistent corneal epithelial defect associated with erlotinib treatment Cornea 28 2009 706 707
19. S. Yeh, H.A. Fine, J.A. Smith Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma Cornea 28 2009 699 702
20. G. Zhang, S. Basti, L.M. Jampol Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature Cornea 26 2007 858 860
21. A.B. Methvin, R.E. Gausas Newly recognized ocular side effects of erlotinib Ophthal Plast Reconstr Surg 23 2007 63 65
22. C.M. Rocha-Lima, H.P. Soares, L.E. Raez, R. Singal EGFR targeting of solid tumors Cancer Control 14 2007 295 304
23. M. Jost, C. Kari, U. Rodeck The EGF receptor - an essential regulator of multiple epidermal functions Eur J Dermatol 10 2000 505 510
24. M. Van den Eynde, J.F. Baurain, F. Mazzeo, J.P. Machiels Epidermal growth factor receptor targeted therapies for solid tumours Acta Clin Belg 66 2011 10 17
25. M.S. Ballas, A. Chachoua Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC Onco Targets Ther 4 2011 43 58
26. N. Mittmann, S.J. Seung Rash rates with EGFR inhibitors: meta-analysis [report online] Curr Oncol 18 2011 e54 e63 http://www.current-oncology.com/ index.php/oncology/article/view/605/ Accessed February 28, 2012
27. R. Perez-Soler, J.P. Delord, A. Halpern HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR Inhibitor Rash Management Forum Oncologist 10 2005 345 356
28. R. Perez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
29. L.G. Morris, H.S. Hochster, M.D. Delacure Eyelash trichomegaly secondary to panitumumab therapy Curr Oncol 18 2011 145 146
30. R. Papadopoulos, V. Chasapi, A. Bachariou Trichomegaly induced by erlotinib Orbit 27 2008 329 330
31. K. Lane, S.M. Goldstein Erlotinib-associated trichomegaly Ophthal Plast Reconstr Surg 23 2007 65 66
32. R.U. Desai, L.P. Rachakonda, N.A. Saffra Trichomegaly secondary to erlotinib [letter][report online] Can J Ophthalmol 44 2009 e65
33. M.W. Saif, J. Gnanaraj Erlotinib-induced trichomegaly in a male patient with pancreatic cancer Cutan Ocul Toxicol 29 2010 62 66
34. P.R. Cohen, S.M. Escudier, R. Kurzrock Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors Am J Clin Dermatol 12 2011 63 67
35. R. Bambury, J.A. McCaffrey Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab [letter] Clin Colorectal Cancer 8 2009 235
36. B.J. Frankfort, D.C. Garibaldi Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling [letter] Ophthal Plast Reconstr Surg 23 2007 496 497
37. S.E. Wilson, Y.G. He, J. Weng Effect of epidermal growth factor, hepatocyte growth factor, keratinocyte growth factor on proliferation, motility and differentiation of human corneal epithelial cells Exp Eye Res 59 1994 665 678
38. A.B. Tullo, B. Esmaeli, P.I. Murray Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor geftinib ('Iressa', ZD1839) in phase I and II clinical trials Eye (Lond) 19 2005 729 738
39. C.G. Förster, C. Cursiefen, F.E. Kruse Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment [in German] Ophthalmologe 105 2008 269 273
40. F.T. Fraunfelder, F.W. Fraunfelder Trichomegaly and other external eye side effects associated with epidermal growth factor Cutan Ocul Toxicol 2011 Nov 28 [Epub ahead of print]
41. S.T. Feldman The effect of epidermal growth factor on corneal wound healing: practical considerations for therapeutic use Refract Corneal Surg 7 1991 232 239
42. E.B. Márquez, D. De Ortueta, S.B. Royo, P.A. Martínez- Carpio Epidermal growth factor receptor in corneal damage: update and new insights from recent reports Cutan Ocul Toxicol 30 2011 7 14
43. S. Basti Ocular toxicities of epidermal growth factor receptor inhibitors and their management Cancer Nurs 30 Suppl 2007 S10 S16